Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical Cancer
Primary Purpose
Cervical Cancer
Status
Completed
Phase
Not Applicable
Locations
Taiwan
Study Type
Interventional
Intervention
Surepath
Conventional Pap smear
Sponsored by
About this trial
This is an interventional screening trial for Cervical Cancer
Eligibility Criteria
Inclusion Criteria:
- All women who had received radiotherapy for cervical cancer in our outpatient clinics.
- Prior to joining test subjects for 90 days or more earlier had received a complete pelvic radiation therapy, including treatment of the cervix or vagina.
- Subjects with radiation therapy (including combined chemical and radiation therapy or postoperative adjuvant [chemical] radiation therapy) for their first treatment.
Exclusion Criteria:
- recurrence of cervical cancer
- hormone treatment within 90 days
- vaginal vault or cervix topical treatment within 90 days.
- Subjects had or now have other malignancies
Sites / Locations
- Far Eastern Memorial Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Women with cervical cancer receive Surepath for screening
Women receive conventional Pap smear for screening
Arm Description
Women will receive Surepath as a tool for screening the recurrence of cervical cancer.
Women who will receive conventional Pap smear for screening
Outcomes
Primary Outcome Measures
the Percentage of Smears, That Were Difficulty in Making a Definite Diagnosis
Comparing the percentage of smears, that were difficulty in making a definite diagnosis from smear owing to insufficient cells, between Surepath® and Conventional Smear in Women after Radiation Therapy for Cervical Cancer
Secondary Outcome Measures
Full Information
NCT ID
NCT01988376
First Posted
August 16, 2013
Last Updated
December 11, 2018
Sponsor
Far Eastern Memorial Hospital
Collaborators
Gynecologic Oncology Group
1. Study Identification
Unique Protocol Identification Number
NCT01988376
Brief Title
Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical Cancer
Study Type
Interventional
2. Study Status
Record Verification Date
July 2015
Overall Recruitment Status
Completed
Study Start Date
March 2012 (undefined)
Primary Completion Date
December 2013 (Actual)
Study Completion Date
November 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Far Eastern Memorial Hospital
Collaborators
Gynecologic Oncology Group
4. Oversight
5. Study Description
Brief Summary
Background/Purpose: This is a large scale, multicenter randomized clinical trial to assess the feasibility of using SurePath® in cervical cancer patients after radiation therapy by comparing the incidence of unsatisfactory smear and the accuracy of detecting cervicovaginal lesions between the SurePath® and the conventional smear.
Patients and Methods: The investigators will invite all women who had received radiotherapy for cervical cancer in the investigators outpatient clinics. All enrolled cases will ask to receive randomly the SurePath® or the conventional smear.
Expected Results: The investigators will get the incidence of unsatisfactory smear and the accuracy of detecting cervicovaginal lesions between the SurePath® and the conventional smear in patients who underwent radiotherapy.
Detailed Description
Adequate specimen (specimen adequacy) is cervical or vaginal cytology single most important quality factors. 2001 Pap Bethesda System classification maintain its previous version, the Pap specimen is divided into satisfactory assessment and unsatisfactory evaluation two kinds; meet "satisfactory assessments "specimen standard, conventional Pap (conventional smear) requires at least 8,000-12,000-readable squamous cells, and liquid-based Pap (liquid-based smear) you need at least 5,000-readable squamous cell .
For squamous cell samples were determined to be adequate, yet to record their specimens have intrauterine neck or squamous transitional zone (transformation zone) border zone cells exist; quality indicators "Cell interpretation in part by inflammation or blood masking noise "of the specimen, if it can not be sentenced to 50-75% of epithelial cells can still be classified as read" satisfied "with the specimen, while more than 75% of the epithelial cells are obscured interference specimen is classified in the" unsatisfactory "specimen.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cervical Cancer
7. Study Design
Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
258 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Women with cervical cancer receive Surepath for screening
Arm Type
Experimental
Arm Description
Women will receive Surepath as a tool for screening the recurrence of cervical cancer.
Arm Title
Women receive conventional Pap smear for screening
Arm Type
Active Comparator
Arm Description
Women who will receive conventional Pap smear for screening
Intervention Type
Device
Intervention Name(s)
Surepath
Intervention Description
A liquid-base method of Pap smear for screening the recurrence of cervical cancer
Intervention Type
Device
Intervention Name(s)
Conventional Pap smear
Intervention Description
Conventional Pap smear
Primary Outcome Measure Information:
Title
the Percentage of Smears, That Were Difficulty in Making a Definite Diagnosis
Description
Comparing the percentage of smears, that were difficulty in making a definite diagnosis from smear owing to insufficient cells, between Surepath® and Conventional Smear in Women after Radiation Therapy for Cervical Cancer
Time Frame
1 year
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
99 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
All women who had received radiotherapy for cervical cancer in our outpatient clinics.
Prior to joining test subjects for 90 days or more earlier had received a complete pelvic radiation therapy, including treatment of the cervix or vagina.
Subjects with radiation therapy (including combined chemical and radiation therapy or postoperative adjuvant [chemical] radiation therapy) for their first treatment.
Exclusion Criteria:
recurrence of cervical cancer
hormone treatment within 90 days
vaginal vault or cervix topical treatment within 90 days.
Subjects had or now have other malignancies
Facility Information:
Facility Name
Far Eastern Memorial Hospital
City
Banqiao
State/Province
New Taipei
ZIP/Postal Code
22050
Country
Taiwan
12. IPD Sharing Statement
Learn more about this trial
Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical Cancer
We'll reach out to this number within 24 hrs